Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 80/100

Failure Rate

33.3%

2 terminated/withdrawn out of 6 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

17%

1 trials in Phase 3/4

Results Transparency

50%

1 of 2 completed trials have results

Key Signals

2 recruiting1 with results

Enrollment Performance

Analytics

N/A
3(75.0%)
Phase 3
1(25.0%)
4Total
N/A(3)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT06438315Recruiting

SuperSaturated Oxygen Comprehensive Observational Registry

Role: lead

NCT04743245Not ApplicableRecruiting

Delivery SSO2 Therapy for 60 Min in Anterior MI Patients With PCI ≤ 6 Hours of Symptoms Onset Compared to Standard.

Role: lead

NCT05156996Terminated

A Prospective Real-World Multi-Center Post-Market Observational Evaluation of Supersaturated O2 Therapy Using the TherOx® Downstream® System

Role: lead

NCT04876040Not ApplicableWithdrawn

Incorporating Supersaturated Oxygen in Shock

Role: lead

NCT02603835Not ApplicableCompleted

Evaluation of Intracoronary Hyperoxemic Oxygen Therapy in Anterior Acute Myocardial Infarction Patients (IC-HOT)

Role: lead

NCT00175058Phase 3Completed

Acute Myocardial Infarction With HyperOxemic Therapy II (AMIHOT II)

Role: lead

All 6 trials loaded